



C014CIP/SPV1/66

TECH CENTER 1600/2900

DEC 19 2001

RECEIVED

#13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Phillip Gambel
Group Art Unit : 1644
Applicants : Michael J. Yellin et al.
Application No.: 09/343,001 Confirmation No.: 7400
Filed : JUNE 29, 1999
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF VASCULITIS

New York, New York
December 4, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

Sir:

Pursuant to 37 C.F.R. § 1.97(d), applicants hereby request consideration of the Fourth Supplemental Information Disclosure Statement incorporated herein below. This Fourth Supplemental Information Disclosure Statement cites documents recently cited in a September 18, 2001 Supplementary European Search Report in applicants' corresponding European patent application.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

In the below-incorporated Fourth Supplemental Information Disclosure Statement, applicants state, as required by 37 C.F.R. § 1.97 (d)(1) and pursuant to 37 C.F.R. § 1.97 (e)(1), that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

A check in the amount of \$180.00, in payment of the fee as set forth in 37 C.F.R. § 1.17(p) is enclosed herewith. In the accompanying Transmittal Letter, the Director is hereby authorized to charge any additional fee due, or refund any overpayment made, in connection with this Statement, to Deposit Account No. 06-1075.

Accordingly, consideration of the Fourth Supplemental Information Disclosure Statement is respectfully requested.

Fourth Supplemental Information Disclosure Statement

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), applicants make of record the following documents, copies of which are submitted herewith:

Other Documents

Fred Ramsdell et al., "CD40 Ligand Acts As a Costimulatory Signal for Neonatal Thymic Yδ T Cells", *J. Immunol.* 152:2190 (1994).

Josette Peguet-Navarro et al., "Functional Expression of CD40 Antigen on Human Epidermal Langerhans Cells", *J. Immunol.* 155:4241-4247 (1995).

Peter A. Kiener et al., "Stimulation of CD40 with Purified Soluble gp39 Induces Proinflammatory Responses in Human Monocytes", *J. Immunol.* 155:4917-4925 (1995).

For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

The documents are listed because they were cited in the September 18, 2001 Supplementary European Search Report in applicants' corresponding European patent application.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

Consideration of this Fourth Supplemental
Information Disclosure Statement is respectfully requested.

Respectfully submitted,

Shawn-Marie Mayrand
James F. Haley, Jr. (Reg. No. 27,794)
Margaret A. Pierri (Reg. No. 30,709)
Attorneys for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax : (212) 596-9090

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on

December 4, 2001
Lillian Garcia

Lillian Garcia
Signature of Person Signing